Rinvoq (upadacitinib) / AbbVie  >>  Phase 3
Welcome,         Profile    Billing    Logout  

49 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rinvoq (upadacitinib) / AbbVie
NCT04666675: A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil

Withdrawn
3b
0
NA
Upadacitinib, Rinvoq, ABT-494, Placebo for Upadacitinib
AbbVie
Atopic Dermatitis (AD)
03/21
03/21
SELECT-BEYOND, NCT02706847 / 2015-003335-35: A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs

Checkmark Safety and efficacy of SELECT-BEYOND study in subjects with rheumatoid arthritis
Nov 2022 - Nov 2022: Safety and efficacy of SELECT-BEYOND study in subjects with rheumatoid arthritis
Checkmark SELECT-BEYOND
Sep 2017 - Sep 2017: SELECT-BEYOND
Completed
3
499
Europe, Canada, US, RoW
Placebo, Upadacitinib, ABT-494, RINVOQ®
AbbVie
Rheumatoid Arthritis
04/17
02/22
SELECT-NEXT, NCT02675426 / 2015-003332-13: A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone

Checkmark Safety and efficacy of SELECT-NEXT study in subjects with rheumatoid arthritis
Nov 2022 - Nov 2022: Safety and efficacy of SELECT-NEXT study in subjects with rheumatoid arthritis
Checkmark From SELECT-NEXT study in csDMARD-IR Patients
Jun 2017 - Jun 2017: From SELECT-NEXT study in csDMARD-IR Patients
Checkmark SELECT-NEXT trial in RA
More
Completed
3
661
Europe, Canada, US, RoW
Placebo, Upadacitinib, ABT-494, Rinvoq
AbbVie
Rheumatoid Arthritis
04/17
03/22
SELECT-MONOTHERAPY, NCT02706951 / 2015-003376-75: A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX

Completed
3
648
Europe, Japan, US, RoW
Methotrexate, Upadacitinib, ABT-494, Rinvoq, Placebo Upadacitinib, Placebo Methotrexate
AbbVie
Rheumatoid Arthritis
10/17
08/22
SELECT-COMPARE, NCT02629159 / 2015-003333-95: A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

Hourglass May 2023 - Jun 2023 : Presentation of data from SELECT-COMPARE trial for rheumatoid arthritis at EULAR 2023
Checkmark SELECT-COMPARE new long-term data
Jun 2019 - Jun 2019: SELECT-COMPARE new long-term data
Checkmark Integrated safety data in five SELECT trials
Jun 2019 - Jun 2019: Integrated safety data in five SELECT trials
More
Active, not recruiting
3
1629
Europe, Canada, US, RoW
Placebo for Adalimumab, Adalimumab, Humira, Placebo for Upadacitinib, Upadacitinib, ABT-494
AbbVie
Rheumatoid Arthritis
10/17
09/27
SELECT-EARLY, NCT02706873 / 2015-003334-27: A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate

Checkmark SELECT-EARLY new long-term data
Jun 2019 - Jun 2019: SELECT-EARLY new long-term data
Checkmark Integrated safety data in five SELECT trials
Jun 2019 - Jun 2019: Integrated safety data in five SELECT trials
Checkmark Safety and efficacy data
More
Completed
3
1002
Europe, Canada, Japan, US, RoW
Placebo to Upadacitinib, Methotrexate, Placebo to Methotrexate, Upadacitinib, ABT-494, Rinvoq
AbbVie
Rheumatoid Arthritis
03/18
11/22
SELECT-CHOICE, NCT03086343 / 2016-000933-37: A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Checkmark Efficacy and safety data from SELECT-CHOICE trial at EULAR 2020
Jun 2020 - Jun 2020: Efficacy and safety data from SELECT-CHOICE trial at EULAR 2020
Checkmark SELECT-CHOICE trial
Oct 2018 - Oct 2018: SELECT-CHOICE trial
Completed
3
657
Europe, Canada, US, RoW
Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, ABT-494, Placebo for upadacitinib
AbbVie
Rheumatoid Arthritis (RA)
06/19
06/23
SELECT - PsA 2, NCT03104374 / 2016-004152-30: A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

Checkmark From SELECT PsA 2 trial for psoriatic arthritis
May 2020 - May 2020: From SELECT PsA 2 trial for psoriatic arthritis
Completed
3
642
Europe, Canada, Japan, US, RoW
Placebo, Upadacitinib, ABT-494
AbbVie
Psoriatic Arthritis
07/19
09/24
NCT02955212: A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)

Completed
3
338
RoW
Upadacitinib, ABT-494, RINVOQ™, Placebo
AbbVie
Rheumatoid Arthritis (RA)
08/19
09/20
SELECT - PsA 1, NCT03104400 / 2016-004130-24: A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

Hourglass May 2023 - Jun 2023 : Presentation of data from SELECT - PsA 1 trial for psoriatic arthritis at EULAR 2023
Checkmark Efficacy and safety data from SELECT - PsA 1 study in psoriatic arthritis
Apr 2021 - Apr 2021: Efficacy and safety data from SELECT - PsA 1 study in psoriatic arthritis
Checkmark Positive top-line results from SELECT-PsA 1 trial
Feb 2020 - Feb 2020: Positive top-line results from SELECT-PsA 1 trial
Completed
3
1705
Europe, Canada, Japan, US, RoW
Adalimumab, Humira®, Upadacitinib, ABT 494, RINVOQ®, Placebo to Upadacitinib, Placebo to Adalimumab
AbbVie
Psoriatic Arthritis
09/19
09/24
2020-001899-14: An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunosuppressive medication can be tapered without recurrence of symptoms

Not yet recruiting
3
270
Europe
Prednisolone p.o., Sulfasalazine, Leflunomide, Methotrexate p.o., Methotrexate s.c., Etanercept, Adalimumab, Infliximab, Abatacept s.c., Abatacept i.v., Tablet, Coated tablet, , Solution for injection, Powder for concentrate for solution for infusion, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Solution for injection in dose-dispenser cartridge, Prolonged-release tablet, Xeljanz 5/10mg Filmtabletten, Otezla Filmtabletten, Simponi 50mg Injektionslösung Vorgefüllter Injektor/Fertigspritze, Cimzia 200mg Injektionslösung in einem Fertigpen, Orencia Injektionslösung in einer Fertigspritze, Orencia 250mg Pulver, Cosentyx 150mg Injektionslösung in einer Fertigspritze, Taltz, Cimzia 200mg Injektionslösung in einer Fertigspritze, Cimzia 200mg Injektionslösung in einer Patrone für ein Dosiergerät, Orencia 125mg Injektionslösung im Fertigpen, Cosentyx 150mg Injektionslösung in einem Fertigpen, Stelara 45mg/90mg Injektionslösung, Xeljanz 11mg Retardtablette, Rinvoq 15 mg Retardtablette, Tremfya 100mg Injektionslösung, Skyrizi 75/150mg Injektionslösung
Universitätsklinikum Erlangen, Universitätsklinikum Erlangen
Psoriatic arthritis Psoriasisarthritis, Psoriatic arthritis Gelenkbeteiligung bei Schuppenflechte, Diseases [C] - Immune System Diseases [C20]
 
 
NCT03738397 / 2018-002264-57: A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

Checkmark Efficacy and safety data from Heads Up study for atopic dermatitis
Dec 2020 - Dec 2020: Efficacy and safety data from Heads Up study for atopic dermatitis
Checkmark Data from Heads-Up trial for atopic dermatitis
Dec 2020 - Dec 2020: Data from Heads-Up trial for atopic dermatitis
Completed
3
673
Europe, Canada, US, RoW
Upadacitinib, ABT-494, RINVOQ®, Dupilumab, Dupixent®, Placebo to dupilumab, Placebo to upadacitinib
AbbVie
Atopic Dermatitis
08/20
12/20
MEASURE-UP-1, NCT03569293 / 2017-005125-20: Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

Checkmark Efficacy and safety data in adolescent and adult patients with moderate to severe atopic dermatitis
Jun 2020 - Jun 2020: Efficacy and safety data in adolescent and adult patients with moderate to severe atopic dermatitis
Completed
3
912
Europe, Canada, Japan, US, RoW
Placebo for Upadacitinib, Upadacitinib, ABT-494, RINVOQ™
AbbVie
Atopic Dermatitis
01/21
10/25
U-Accomplish, NCT03653026 / 2016-000642-62: A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

Hourglass May 2022 - May 2022 : Efficacy and safety data from U-ACCOMPLISH trial for ulcerative colitis
Checkmark Efficacy and safety data from U-ACCOMPLISH trial for ulcerative colitis
May 2022 - May 2022: Efficacy and safety data from U-ACCOMPLISH trial for ulcerative colitis
Checkmark Efficacy and safety data from U-ACCOMPLISH trial for ulcerative colitis
Feb 2021 - Feb 2021: Efficacy and safety data from U-ACCOMPLISH trial for ulcerative colitis
More
Completed
3
522
Europe, Canada, Japan, US, RoW
Placebo, Upadacitinib, ABT-494, RINVOQ®
AbbVie
Ulcerative Colitis (UC)
01/21
01/21
AD Up, NCT03568318 / 2017-005126-37: A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Active, not recruiting
3
1533
Europe, Canada, Japan, US, RoW
Placebo, Upadacitinib, ABT-494, RINVOQ™, Topical corticosteroids (TCS)
AbbVie
Atopic Dermatitis
02/21
10/30
MEASURE-UP-2, NCT03607422 / 2018-001383-28: A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

Checkmark Efficacy and safety data from Measure Up 2 study in moderate to severe atopic dermatitis
Jul 2020 - Jul 2020: Efficacy and safety data from Measure Up 2 study in moderate to severe atopic dermatitis
Checkmark Trial initiation
Jul 2018 - Jul 2018: Trial initiation
Completed
3
912
Europe, Canada, US, RoW
Placebo for Upadacitinib, Upadacitinib, ABT-494, RINVOQ®
AbbVie
Atopic Dermatitis
03/21
11/25
NCT03345836 / 2017-001226-18: A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

Checkmark From trial for moderate to severe Crohn's disease
Dec 2021 - Dec 2021: From trial for moderate to severe Crohn's disease
Completed
3
624
Europe, Canada, Japan, US, RoW
Matching Placebo for Upadacitinib, Upadacitinib, ABT-494, RINVOQ®
AbbVie, AbbVie Inc.
Crohn's Disease
08/21
08/21
SELECT AXIS 2, NCT04169373 / 2019-003229-12: A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

Hourglass May 2023 - Jun 2023 : Data from SELECT AXIS 2 trial for axial spondyloarthritis at EULAR 2023
Checkmark Safety and efficacy data from study 1 of SELECT-AXIS 2 trial in patients with active ankylosing spondylitis
Oct 2021 - Oct 2021: Safety and efficacy data from study 1 of SELECT-AXIS 2 trial in patients with active ankylosing spondylitis
Checkmark Safety and efficacy data from study 2 of SELECT-AXIS 2 in adults with active non-radiographic axial spondyloarthritis
Oct 2021 - Oct 2021: Safety and efficacy data from study 2 of SELECT-AXIS 2 in adults with active non-radiographic axial spondyloarthritis
Completed
3
734
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494, RINVOQ, Placebo
AbbVie
Spondyloarthritis
09/21
02/25
U-EXCEL, NCT03345849 / 2017-001240-35: A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

Checkmark Safety and efficacy of U-EXCEL study in subjects with moderately to severely active Crohn's disease
Oct 2022 - Oct 2022: Safety and efficacy of U-EXCEL study in subjects with moderately to severely active Crohn's disease
Checkmark Efficacy and safety of U-EXCEL study in with moderately to severely active Crohn's disease
Oct 2022 - Oct 2022: Efficacy and safety of U-EXCEL study in with moderately to severely active Crohn's disease
Checkmark Safety and efficacy data from U-EXCEL trial in crohn's disease
More
Completed
3
526
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494, RINVOQ, Placebo for Upadacitinib
AbbVie
Crohn's Disease
10/21
01/22
NCT03661138 / 2022-002777-29: A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Completed
3
272
Japan
Upadacitinib, ABT-494, Placebo for upadacitinib, Topical Corticosteroids (TCS)
AbbVie, AbbVie Inc
Atopic Dermatitis
08/22
08/22
upadacetinib, NCT06758947: Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF

Completed
3
60
RoW
Upadacitinib 15 MG, Upadacitinib, Cellcept Oral Product, MMF
Assiut University
Interstitial Lung Disease Due to Systemic Disease (Disorder)
06/24
11/24
NCT04195698 / 2019-001227-12: Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

Completed
3
475
Europe, Canada, US, RoW
Upadacitinib, ABT-494, RINVOQ
AbbVie, AbbVie Inc.
Atopic Dermatitis
09/23
09/23
SYBRA, NCT05379322: The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients

Withdrawn
3
145
RoW
Anti-TNF, Adalimumab, etanercept, certolizumab, or golimumab, JAK inhibitor, Tofacitinib, baricitinib, or upadacitinib
Abu Dhabi Stem Cells Center
Rheumatoid Arthritis
03/23
03/23
DOPPLER, NCT05121298: Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate

Recruiting
3
155
Japan
upadacitinib 15mg/day
Atsushi Kawakami, AbbVie GK.
Rheumatoid Arthritis, JAK Inhibitor, Musculoskeletal Ultrasound, Biomarker
11/23
09/24
SELECT-GCA, NCT03725202 / 2017-003978-13: A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

Jan 2024 - Dec 2024: Regulatory submission for giant cell arteritis
Jan 2024 - Dec 2024: Data readout from SELECT-GCA trial for giant cell arteritis
Checkmark Initiation of P3 trial in giant cell arteritis
Feb 2019 - Feb 2019: Initiation of P3 trial in giant cell arteritis
Checkmark Trial initiation
More
Completed
3
438
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494, RINVOQ, Corticosteroid (CS), Placebo
AbbVie
Giant Cell Arteritis (GCA)
02/24
02/25
Level Up, NCT05601882 / 2022-002482-15: A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Completed
3
920
Europe, Canada, Japan, US, RoW
Dupilumab, Dupixent®, Upadacitinib, ABT-494, RINVOQ
AbbVie, AbbVie Inc.
Atopic Dermatitis
03/24
08/24
SELECT-TAK, NCT04161898: A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)

Active, not recruiting
3
56
Japan, RoW
Upadacitinib, ABT-494, RINVOQ, Placebo for Upadacitinib, Prednisolone
AbbVie
Takayasu Arteritis (TAK)
08/27
08/27
Sleep Up, NCT06390722: A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis

Withdrawn
3
112
NA
Upadacitinib, RINVOQ, Placebo for Upadacitinib
AbbVie
Atopic Dermatitis, Sleep Disturbance
01/26
07/26
Switch-Up, NCT06389136: A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Recruiting
3
200
Canada, Japan, US, RoW
Upadacitinib 15mg Dose, ABT-494, RINVOQ, Dupilumab 300mg Dose, Upadacitinib 30mg Dose
AbbVie
Atopic Dermatitis
08/26
03/27
NCT06332534: Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

Recruiting
3
110
Europe, Canada, Japan, US, RoW
Upadacitinib, RINVOQ
AbbVie
Crohn's Disease
06/27
12/34
Start Up, NCT06461897: A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

Recruiting
3
675
Europe, Canada, US, RoW
Upadacitinib, ABT-494, RINVOQ®, RINVOQ LQ, Dupilumab
AbbVie
Atopic Dermatitis
07/30
07/30
Start Up Japan, NCT06701331: Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis

Recruiting
3
98
Japan
Placebo, ABT-494, RINVOQ®, Upadacitinib
AbbVie
Atopic Dermatitis
01/27
01/27
VICTRIVA, NCT06227910: A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

Recruiting
3
396
Europe, Canada, US, RoW
Vedolizumab, Entyvio, MLN0002, KYNTELES, Upadacitinib, Rinvoq, Placebo
Takeda
Crohn's Disease
06/27
08/28
RESCUE UC, NCT06660693: Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis

Recruiting
3
134
Canada
Upadacitinib Oral Product
McMaster University, AbbVie
Colitis, Ulcerative
05/27
09/27
NCT07008846: Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis

Active, not recruiting
3
96
RoW
To see the efficacy of Upadacitinib, Methotrexate versus Tofacitinib, Methotrexate in moderate to severe Rheumatoid arthritis
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Moderate to Severe Rheumatoid Arthritis
09/26
09/26
Up-AA, NCT06012240: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Recruiting
3
1500
Europe, Canada, Japan, US, RoW
Upadacitinib, Rinvoq, ABT-494, Placebo
AbbVie
Alopecia Areata
01/28
01/28
NCT07023302: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata

Recruiting
3
123
Japan
Upadacitinib, Upadacitinib Placebo
AbbVie
Alopecia Areata
02/29
02/29
NCT07149467: Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study

Not yet recruiting
3
454
NA
Ustekinumab (approximately 6 mg/kg), Upadacitinib
Sixth Affiliated Hospital, Sun Yat-sen University
Crohn's Disease Aggravated, Crohn's Disease in Remission
12/26
12/27
NCT06928272: Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study

Recruiting
3
348
Europe, Canada, US, RoW
Pirfenidone, Esbrit, Placebo for pirfenidone, Upadacitinib, Rinvoq, Placebo for upadacitinib
Douglas D. Fraser
Long COVID
12/26
12/27
SELECT- SWITCH, NCT05814627: Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Active, not recruiting
3
487
Europe, Canada, Japan, US, RoW
Upadacitinib, RINVOQ, Adalimumab, Humira, Upadacitinib Matching Placebo, Adalimumab Matching Placebo
AbbVie
Rheumatoid Arthritis
07/26
07/26
Viti-Up, NCT06118411: A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

Hourglass Aug 2025 - Dec 2025 : Top-line data for vitiligo
Active, not recruiting
3
614
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494, Rinvoq, Placebo, NB-UVB (narrow-band ultraviolet B) Phototherapy
AbbVie
Vitiligo
09/25
02/28
Step-Up HS, NCT05889182: A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Recruiting
3
1328
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494, RINVOQ, Placebo
AbbVie
Hidradenitis Suppurativa
03/28
03/28
RA-PROPR, NCT04692493: RA-PRO PRAGMATIC TRIAL

Recruiting
3
924
Canada, US
targeted synthetic DMARD class, non-TNFi-biologic class
University of Alabama at Birmingham, Patient-Centered Outcomes Research Institute
Rheumatoid Arthritis
02/27
12/28
SELECT-SLE, NCT05843643: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Recruiting
3
1000
Europe, Canada, Japan, US, RoW
Upadacitinib, RINVOQ, Placebo
AbbVie
Systemic Lupus Erythematosus
12/26
10/27
NCT05609630: Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Recruiting
3
90
Europe, Japan, US, RoW
Upadacitinib, RINVOQ, ABT-494, Tocilizumab
AbbVie
Juvenile Idiopathic Arthritis
06/29
06/29
U-ACTIVATE LTE, NCT03006068 / 2016-000674-38: A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

Hourglass Aug 2020 - Dec 2020 : Top-line data from trial for ulcerative colitis
Active, not recruiting
3
950
Europe, Canada, Japan, US, RoW
Upadacitinib (ABT-494), RINVOQ, Placebo
AbbVie
Ulcerative Colitis (UC)
07/27
07/27
U-ENDURE, NCT03345823 / 2017-001225-41: A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

Checkmark Data from trial for moderate-severe Crohn’s disease
May 2022 - May 2022: Data from trial for moderate-severe Crohn’s disease
Active, not recruiting
3
747
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494, RINVOQ, Placebo for Upadacitinib
AbbVie
Crohn's Disease
09/27
09/27
U-ASTOUND, NCT05782907: Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

Active, not recruiting
3
122
Europe, Canada, Japan, US, RoW
Upadacitinib, RINVOQ
AbbVie
Ulcerative Colitis
08/28
10/33
U-ACHIEVE, NCT02819635 / 2016-000641-31: A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Checkmark Safety and efficacy of U-ACHIEVE study in subjects with moderately to severely active ulcerative colitis
Oct 2022 - Oct 2022: Safety and efficacy of U-ACHIEVE study in subjects with moderately to severely active ulcerative colitis
Checkmark Efficacy and safety of U-ACHIEVE study in with moderately to severely active ulcerative colitis
Oct 2022 - Oct 2022: Efficacy and safety of U-ACHIEVE study in with moderately to severely active ulcerative colitis
Checkmark Efficacy and safety data of U-ACHIEVE in adults with moderately to severely active ulcerative colitis
More
Completed
2/3
1302
Europe, Canada, Japan, US, RoW
Placebo, Upadacitinib, ABT-494, RINVOQ
AbbVie
Ulcerative Colitis (UC)
12/21
12/21

Download Options